<SEC-DOCUMENT>0001185185-24-000324.txt : 20240328
<SEC-HEADER>0001185185-24-000324.hdr.sgml : 20240328
<ACCEPTANCE-DATETIME>20240327184227
ACCESSION NUMBER:		0001185185-24-000324
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20240322
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240328
DATE AS OF CHANGE:		20240327

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IGC Pharma, Inc.
		CENTRAL INDEX KEY:			0001326205
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				202760393
		STATE OF INCORPORATION:			MD
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-32830
		FILM NUMBER:		24792556

	BUSINESS ADDRESS:	
		STREET 1:		10224 FALLS ROAD
		CITY:			POTOMAC
		STATE:			MD
		ZIP:			20854
		BUSINESS PHONE:		301-983-0998

	MAIL ADDRESS:	
		STREET 1:		10224 FALLS ROAD
		CITY:			POTOMAC
		STATE:			MD
		ZIP:			20854

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	India Globalization Capital, Inc.
		DATE OF NAME CHANGE:	20050505
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>igcpharma20240326_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Wed Mar 27 22:37:24 UTC 2024 -->
<html xmlns:igc="http://www.igcinc.us/20240322" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:compsci="http://compsciresources.com" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml"><head>
	<title>igcpharma20240326_8k.htm</title>

	<!-- Generated by ThunderDome Portal - 3/26/2024 11:17:17 PM -->

<meta content="text/html" http-equiv="Content-Type"/>
</head>
<body><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;"><div>
</div><hr style="height: 3px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0"/><div>
</div><hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 0 0 3pt 0"/><div>
</div><p style="font-family: &quot;Times New Roman&quot;; font-size: 16pt; font-variant: normal; margin: 0pt; text-align: center;"><b>UNITED STATES</b></p><div>

</div><p style="font-family: &quot;Times New Roman&quot;; font-size: 16pt; font-variant: normal; text-align: center; margin: 0pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b></p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Washington, D.C. 20549</b>&#160;</p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><hr class="hr-custom" style="text-align: center;height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 0pt auto 0pt auto;"/><div>
</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family: &quot;Times New Roman&quot;; font-size: 16pt; font-variant: normal; text-align: center; margin: 0pt;"><b>FORM <ix:nonNumeric contextRef="c0" name="dei:DocumentType" id="ixv-379">8-K</ix:nonNumeric></b></p><div>

</div><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">&#160;</p><div>

</div><hr class="hr-custom" style="text-align: center;height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 0pt auto 0pt auto;"/><div>
</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CURRENT REPORT</b></p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934</b></p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="ixv-47"><b><span style="text-decoration:underline">March 22, 2024</span></b></ix:nonNumeric></p><div>

</div><p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="igcpharma20240326_8kimg001.jpg" src="igcpharma20240326_8kimg001.jpg" style="width:96;height:69;"/></p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">	<tr>	<td style="vertical-align:top;width:30%;">&#160;</td>	<td style="vertical-align:top;width:40%;">	<p style="font-family:Times New Roman;font-size:18pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 5pt;"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName" id="ixv-61"><b><span style="text-decoration:underline">IGC PHARMA, INC.</span></b></ix:nonNumeric></p>	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 6pt;">(Exact name of registrant as specified in charter)</p>	</td>	<td style="vertical-align:top;width:30%;">&#160;</td>	</tr>	<tr>	<td style="vertical-align:top;width:30%;">&#160;</td>	<td style="vertical-align:top;width:40%;">&#160;</td>	<td style="vertical-align:top;width:30%;">&#160;</td>	</tr>	<tr>	<td style="vertical-align:top;width:30%;">	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 2pt;"><ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="ixv-73"><b><span style="text-decoration:underline">Maryland</span></b></ix:nonNumeric></p>	</td>	<td style="vertical-align:top;width:40%;">	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 6pt;"><ix:nonNumeric contextRef="c0" name="dei:EntityFileNumber" id="ixv-78"><b><span style="text-decoration:underline">001-32830</span></b></ix:nonNumeric></p>	</td>	<td style="vertical-align:top;width:30%;">	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 13pt;"><ix:nonNumeric contextRef="c0" name="dei:EntityTaxIdentificationNumber" id="ixv-83"><b><span style="text-decoration:underline">20-2760393</span></b></ix:nonNumeric></p>	</td>	</tr>	<tr>	<td style="vertical-align:top;width:30%;">	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 3pt;">(State or other jurisdiction of incorporation)</p>	</td>	<td style="vertical-align:top;width:40%;">	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 6pt;">(Commission File Number)</p>	</td>	<td style="vertical-align:top;width:30%;">	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 13pt;">(I.R.S. Employer Identification No.)</p>	</td>	</tr>	<tr>	<td style="vertical-align:top;width:30%;">&#160;</td>	<td style="vertical-align:top;width:40%;">&#160;</td>	<td style="vertical-align:top;width:30%;">&#160;</td>	</tr>	<tr>	<td style="vertical-align:top;width:30%;">&#160;</td>	<td style="vertical-align:top;width:40%;">	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 5pt;"><b><span style="text-decoration:underline"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1" id="ixv-380">10024 Falls Road</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown" id="ixv-381">Potomac</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="ixv-382">Maryland</ix:nonNumeric> <ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode" id="ixv-383">20859</ix:nonNumeric></span></b></p>	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 5pt;">(Address of principal executive offices) (Zip Code)</p>	</td>	<td style="vertical-align:top;width:30%;">&#160;</td>	</tr>	<tr>	<td style="vertical-align:top;width:30%;">&#160;</td>	<td style="vertical-align:top;width:40%;">&#160;</td>	<td style="vertical-align:top;width:30%;">&#160;</td>	</tr>	<tr>	<td style="vertical-align:top;width:30%;">&#160;</td>	<td style="vertical-align:top;width:40%;">	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 5pt;"><b><span style="text-decoration:underline">(<ix:nonNumeric contextRef="c0" name="dei:CityAreaCode" id="ixv-384">301</ix:nonNumeric>) <ix:nonNumeric contextRef="c0" name="dei:LocalPhoneNumber" id="ixv-385">983-0998</ix:nonNumeric></span></b></p>	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 6pt;">(Registrant&#8217;s telephone number, including area code)</p>	</td>	<td style="vertical-align:top;width:30%;">&#160;</td>	</tr>
</table><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">_____________________________________________________</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Former Name or Former Address, if Changed since Last Report)</p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">	<tr>	<td style="vertical-align:middle;width:1.1%;">&#160;</td>	<td style="vertical-align:top;width:3.3%;">	<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:WrittenCommunications" id="ixv-386">&#9744;</ix:nonNumeric></p>	</td>	<td style="vertical-align:top;width:95.6%;">	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p>	</td>	</tr>	<tr>	<td style="vertical-align:middle;width:1.1%;">&#160;</td>	<td style="vertical-align:top;width:3.3%;">	<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:SolicitingMaterial" id="ixv-387">&#9744;</ix:nonNumeric></p>	</td>	<td style="vertical-align:top;width:95.6%;">	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>	</td>	</tr>	<tr>	<td style="vertical-align:middle;width:1.1%;">&#160;</td>	<td style="vertical-align:top;width:3.3%;">	<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:PreCommencementTenderOffer" id="ixv-388">&#9744;</ix:nonNumeric></p>	</td>	<td style="vertical-align:top;width:95.6%;">	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p>	</td>	</tr>	<tr>	<td style="vertical-align:middle;width:1.1%;">&#160;</td>	<td style="vertical-align:top;width:3.3%;">	<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:PreCommencementIssuerTenderOffer" id="ixv-389">&#9744;</ix:nonNumeric></p>	</td>	<td style="vertical-align:top;width:95.6%;">	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p>	</td>	</tr>
</table><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Securities registered pursuant to Section 12(b) of the Act:</p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">	<tr>	<td style="vertical-align: top; width: 40%; border-top: 1px solid black; border-left: 1px solid black; border-image: initial;">	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Title of each class</b></p>	</td>	<td style="vertical-align: top; width: 20%; border-top: 1px solid black; border-left: 1px solid black; border-image: initial;">	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Trading Symbol(s)</b></p>	</td>	<td style="vertical-align: top; width: 40%; border-top: 1px solid black; border-right: 1px solid black; border-left: 1px solid black; border-image: initial;">	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Name of each exchange on which registered</b></p>	</td>	</tr>	<tr>	<td style="vertical-align: top; width: 40%; border-top: 1px solid black; border-bottom: 1px solid black; border-left: 1px solid black; border-image: initial;">	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="c0" name="dei:Security12bTitle" id="ixv-390">Common Stock, $.0001 par value</ix:nonNumeric></p>	</td>	<td style="vertical-align: top; width: 20%; border-top: 1px solid black; border-bottom: 1px solid black; border-left: 1px solid black; border-image: initial;">	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="c0" name="dei:TradingSymbol" id="ixv-391">IGC</ix:nonNumeric></p>	</td>	<td style="vertical-align: top; width: 40%; border: 1px solid black;">	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="c0" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="ixv-392">NYSE American</ix:nonNumeric></p>	</td>	</tr>
</table><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1934 (&#167;240.12b-2 of this chapter)</p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Emerging growth company <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityEmergingGrowthCompany" id="ixv-393">&#9744;</ix:nonNumeric>.</p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&#160;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div><div>

</div><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p><div>

</div><table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item</b>&#160;<b>1.01</b></p>
			</td>
			<td style="vertical-align:top;width:91%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Entry into a Material Definitive Agreement</b></p>
			</td>
		</tr>

</table><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">On March 22, 2024, IGC Pharma, Inc. (&#8220;IGC&#8221; or the &#8220;Company&#8221;) entered&#160;into the 2024 Share Purchase&#160;Agreement&#160;(the &#8220;2024 SPA&#8221;) with Bradbury Asset Management (Hong Kong) Limited (&#8220;Bradbury&#8221;) relating to the sale and issuance by our company to the investors of an aggregate of 8,823,529 shares of our common stock, for&#160;a&#160;total purchase price of $3,000,000 or $0.34 per share, subject to the terms and subject to the conditions set forth in the 2024 SPA.&#160;&#160;The investment is subject to customary closing conditions, including NYSE approval.&#160;&#160;The investor will receive unregistered shares of IGC common stock.&#160;The 2024 SPA is attached as Exhibit 10.1. After giving effect to the purchase, we will have approximately 75,365,061 shares of common stock outstanding.&#160;&#160;The transaction was not registered under the Securities Act of 1933 in reliance on the exemption provided by Section 4(a)(2) thereof. As per the 2024 SPA, the investor will receive piggyback registration rights subject to certain restrictions.</p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">The Purchase&#160;Agreement&#160;contains certain representations, warranties, and covenants. In addition, both parties have agreed to indemnify each other for losses arising out of breaches of their respective representations, warranties, and covenants and for certain liabilities related to each party&#8217;s business, subject to customary limitations.</p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">The foregoing description of the 2024 Stock Purchase&#160;Agreement&#160;does not purport to be complete and is qualified in its entirety by reference to Exhibit 10.1 hereto, which is incorporated by reference. Except for the historical information contained herein, this report contains forward-looking statements that involve risk and uncertainties, such as statements related to the anticipated closing of the offering. The risks and uncertainties involved include the risks detailed from time to time in our filings with the Securities and Exchange Commission, including our annual report on Form 10-K and quarterly reports on Form 10-Q.</p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item</b>&#160;<b>3.02</b></p>
			</td>
			<td style="vertical-align:top;width:91%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Unregistered Sales of Equity Securities</b></p>
			</td>
		</tr>

</table><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">The disclosure set forth in Item 1.01 is incorporated herein by reference.</p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">If and when the shares are issued, they will be issued pursuant to the exemption contained under Section 4(a)(2) of the Securities Act of 1933, as amended.</p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: top; width: 9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 8.01.</b></p>
			</td>
			<td style="vertical-align: top; width: 91%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Other Events.</b></p>
			</td>
		</tr>

</table><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">On March 26, 2024, we issued&#160;a&#160;press release announcing the investment by Bradbury.&#160;A&#160;copy of the press release is attached as Exhibit 99.1 hereto.</p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item</b>&#160;<b>9.01</b></p>
			</td>
			<td style="vertical-align:top;width:91%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Financial Statements and Exhibits.</b></p>
			</td>
		</tr>

</table><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(d) Exhibits</p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:12.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration:underline">Exhibit No</span>.</b></p>
			</td>
			<td style="vertical-align:middle;width:87.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration:underline">Description</span></b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:12.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.1*</p>
			</td>
			<td style="vertical-align:middle;width:87.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_645636.htm" style="-sec-extract:exhibit;">Share Purchase Agreement, dated March 22, 2024, between IGC Pharma, Inc. and Bradbury Asset Management (Hong Kong) Limited (&#8220;Bradbury&#8221;).*</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:12.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">99.1</p>
			</td>
			<td style="vertical-align:middle;width:87.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_645637.htm" style="-sec-extract:exhibit;">Press release issued by IGC Pharma, Inc. on March 26, 2024.</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:12.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">104</p>
			</td>
			<td style="vertical-align:middle;width:87.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Cover Page Interactive Data File (formatted as Inline XBRL).</p>
			</td>
		</tr>

</table><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">* Certain schedules or similar attachments to this exhibit have been omitted in accordance with Item 601(a)(5) of Regulation S-K.</p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The registrant hereby agrees to furnish supplementally to the Securities and Exchange Commission upon request a copy of any omitted schedule or attachment to this exhibit.</p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&#160;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SIGNATURES</b></p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:50%;">&#160;</td>
			<td colspan="2" style="vertical-align:top;width:38%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>IGC Pharma, Inc.</b></p>
			</td>
			<td style="vertical-align:top;width:12%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:50%;">&#160;</td>
			<td style="vertical-align:top;width:3%;">&#160;</td>
			<td style="vertical-align:top;width:35%;">&#160;</td>
			<td style="vertical-align:top;width:12%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:50%;">&#160;</td>
			<td style="vertical-align:top;width:3%;">&#160;</td>
			<td style="vertical-align:bottom;width:35%;">&#160;</td>
			<td style="vertical-align:top;width:12%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Dated: March 26, 2024</p>
			</td>
			<td style="vertical-align:top;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By:</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:35%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/&#160;Ram Mukunda</p>
			</td>
			<td style="vertical-align:top;width:12%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:50%;">&#160;</td>
			<td style="vertical-align:top;width:3%;">&#160;</td>
			<td style="vertical-align:top;width:35%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Name: Ram Mukunda</p>
			</td>
			<td style="vertical-align:top;width:12%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:50%;">&#160;</td>
			<td style="vertical-align:top;width:3%;">&#160;</td>
			<td style="vertical-align:top;width:35%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Title: CEO</p>
			</td>
			<td style="vertical-align:top;width:12%;">&#160;</td>
		</tr>

</table><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&#160;</div>
</div>
</div>
</div><div>


</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag" id="ixv-396">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey" id="ixv-397">0001326205</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="igc-20240322.xsd" xlink:type="simple"/></ix:references>
<ix:resources><xbrli:context id="c0">
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt9uvRsJTXMeMewLyH9HKj6I6pbvcDxjLAKD9Z7zGpK2qQstFsfCu8xSrtW9H2+v0Xv0rh9+KH/Pz8D0bXTVzCQTQCC6nPug5x3Q1UInPHgbEGZWRPbDSOOR8Wxhx84uVee2wOCsvIBVXQhjcay/jyj+BzF6F5eWXZxkWrE+b343GSqCsHkN4aGrn0sPeSOmktnQGTXPn6z0H7cysELAzGSxof1Oiybcwa0elf5iUnHkQA==] CSR-->
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-03-22</xbrli:startDate>
    <xbrli:endDate>2024-03-22</xbrli:endDate>
  </xbrli:period>
</xbrli:context></ix:resources></ix:header>

</div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ex_645636.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<html><head>
	<title>ex_645636.htm</title>
	<!-- Generated by ThunderDome Portal - 3/26/2024 11:14:44 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Exhibit 10.1</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 1pt;"><b><u>FORM OF SHARE PURCHASE AGREEMENT</u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">STOCK PURCHASE AGREEMENT (this &#8220;Agreement&#8221;) dated as signed by and between IGC Pharma, Inc., a Maryland corporation (the "Company"), and Investor as identified in Exhibit B (the "Investor").</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">WHEREAS, the Investor desires to purchase from the Company, and the Company desires to sell and issue to the Investor, shares in IGC (the "Shares") Common Stock, par value $0.0001 per share, ("Common Stock") upon the terms and conditions set forth in this Agreement; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">WHEREAS, in the Investor's purchase of the Shares will be subject to certain restrictions on the transfer of the Shares, all as more fully set forth in this Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">NOW, THEREFORE, in consideration of the mutual terms, conditions and other agreements set forth herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound hereby, the parties hereto hereby agree to the sale and purchase of the Shares as set forth herein.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Definitions.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">For purposes of this Agreement, the terms set forth below shall have the corresponding meanings provided below.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">"Affiliate" shall mean, with respect to any specified Person, (i) if such Person is an individual, the spouse, heirs, executors, or legal representatives of such individual, or any trusts for the benefit of such individual or such individual's spouse and/or lineal descendants, or (ii) otherwise, another Person that directly, or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with, the Person specified. As used in this definition, "control" shall mean the possession, directly or indirectly, of the sole and unilateral power to cause the direction of the management and policies of a Person, whether through the ownership of voting securities or by contract or another written instrument.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">"Business Day" shall mean any day on which banks located in New York are not required or authorized by law to remain closed.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">"Person" shall mean an individual, entity, corporation, partnership, association, limited liability company, limited liability partnership, joint-stock company, trust, or unincorporated organization.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">"Transfer" shall mean any sale, transfer, assignment, conveyance, charge, pledge, mortgage, encumbrance, hypothecation, security interest or other disposition, other than to an Affiliate, or to make or effect any of the above.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sale and Purchase of Shares.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">2.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subscription for Shares by Investor. Subject to the terms and conditions of this Agreement, the Investor hereby agrees to purchase the Shares from the Company, and the Company hereby agrees to issue and sell the Shares to the Investor, in the aggregate number of Shares as set out in Exhibit A. The purchase price for the Shares is as set out in Exhibit A. The investor acknowledges that the purchase price per share is at or above the closing price of IGC, as reflected by NYSE.com, on the day immediately prior to this purchase. The aggregate purchase price is as set out in Exhibit A (the "Consideration").</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">2.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Closing; Deliveries.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The closing of the acquisition of the Shares (the "Closing") shall take place at the offices of Olshan Frome Wolosky LLP, counsel to the Company, at 1325 Avenue of the Americas, New York, New York 10019, or at such other place as the parties may mutually agree on such date and time on which the parties may mutually agree (the "Closing Date").</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At or promptly after the Closing, the Company shall deliver to the Investor, against delivery by the Investor of the Consideration (as provided below), a duly issued Stock Certificate, or a Direct Registration System (DRS) certificate, representing the number of Shares purchased by the Investor as set forth above. The Consideration shall be paid by wire transfer of immediately available funds in accordance with wire transfer instructions provided by the Company in Exhibit A.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Representations, Warranties and Acknowledgments of the Investor.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">The Investor hereby represents, warrants, and acknowledges to the Company as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">3.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Execution, Delivery and Performance.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="1" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">1</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">The Investor has full right, power, and authority to execute and deliver this Agreement and to perform its obligations hereunder and this Agreement has been duly authorized, executed and delivered by it and is valid, binding, and enforceable against it in accordance with its terms.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">3.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No Conflicts.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">None of the execution, delivery and performance of this Agreement by the Investor will conflict with or result in a breach of any terms or provisions of, or constitute a default under, any material contract, agreement, or instrument to which the Investor is a party or by which the Investor is bound.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">3.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investment Representations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Investor understands that the offering and sale of the Shares is intended to be exempt from registration under the Securities Act of 1933, as amended (the "Securities Act"), by virtue of the provisions of Section 4(a)(2) of the Securities Act and Regulation D and/or Regulation S adopted thereunder. The Investor is acquiring the Shares solely for purposes of investment and with no present intention to distribute such Shares. The Investor is an "accredited investor," as defined in Rule 501 of Regulation D, and it has such knowledge and experience in financial and business affairs as to be capable of evaluating the merits and risks of an investment in the Company pursuant to the terms of this Agreement.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Investor understands that (i) the purchase of the Shares is a speculative investment which involves a high degree of risk of loss of the Investor's investment therein, (ii) there are substantial restrictions on the transferability of the Shares under the terms hereof and the provisions of the Securities Act and (iii) following the Closing there may not be an active public market for the Shares and, accordingly, it may not be possible to liquidate its investment in the Company in case of emergency, or otherwise.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">3.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Access to Information; Reliance.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">The Investor has been provided an opportunity to ask questions of, and has received answers thereto satisfactory to it from, the Company and its representatives concerning the Company and the Investor's investment therein, and the Investor has been provided with such information as it has requested from the Company concerning the same. The Investor has sought independent legal, investment and tax advice to the extent that it has deemed necessary or appropriate in connection with its decision to invest in the Company.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">3.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investor Information.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">The information concerning the Investor set forth on the signature page hereof is true and correct. The Investor shall promptly notify the Company and provide the Company with corrected information should any of such Investor information cease to be correct following the date hereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">3.6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Involvement in Certain Legal Proceedings.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">The Investor:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;has not filed or had filed against it a petition under the federal bankruptcy laws or any state insolvency law, or had a receiver, fiscal agent or similar officer appointed by a court for its business or property or any partnership, corporation or business association in which it was a general partner or executive officer at or within five years before the time of such filing;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;has not been convicted in a criminal proceeding, and is not a named subject of a pending criminal proceeding (excluding traffic violations and other minor offenses);</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;has not been the subject of any order, judgment or decree, not subsequently reversed, suspended or vacated, of any federal or state authority or court of competent jurisdiction, permanently or temporarily barring, limiting or enjoining it from engaging in, or otherwise limiting its ability to engage in or be associated with any Person engaged in, any type of business practice, conduct or employment (including without limitation in connection with the purchase or sale of any security or commodity); and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;has not been found by a court of competent jurisdiction in a civil action or by the Securities and Exchange Commission (the "SEC") or the Commodity Futures Trading Commission to have violated any federal or state securities law or federal commodities law, and the judgment in such civil action or finding by such Commission has not been subsequently reversed, suspended or vacated.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Representations and Warranties of the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">The Company represents and warrants to the Investor as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">4.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Execution, Delivery and Performance.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">The Company has the corporate power and authority to execute and deliver this Agreement and to perform its obligations hereunder. This Agreement has been duly authorized, executed and delivered by the Company and is valid, binding, and enforceable against the Company in accordance with its terms.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="2" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">2</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">4.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares Duly Authorized.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">The Shares to be issued to the Investor pursuant to this Agreement, when issued and delivered in accordance with the terms of this Agreement, will be duly and validly issued and will be fully paid and nonassessable.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">4.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No Conflicts.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">None of the execution, delivery and performance of this Agreement by the Company will conflict with the Company's Certificate of Incorporation or By-laws, as amended to date, or result in a breach of any terms or provisions of, or constitute a default under, any material contract, agreement or instrument to which the Company is a party or by which the Company is bound.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">4.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Capitalization.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">As of the date hereof and as of the Closing Date, the Company has approximately 66,541,532 shares issued and outstanding, and Company warrants and options as of the date of this agreement. In addition, Investor acknowledges that the current</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">management shall be issued shares pursuant to the employee equity incentive plans that will cause dilution in the number of shares outstanding.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">4.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">Except as set forth in the SEC Documents (defined below), the Company (a) has no material debts or obligations of any kind or nature whatsoever, secured or unsecured, contingent or absolute, present or past or of any other kind; (b) has no material federal or state income, withholding or other taxes due or owing; (c) has no material employment or other agreements, oral or written, presently in force; (d) has no legal proceedings, judgments or investigations pending, contemplated or threatened against or affecting it; (e) owes no material fees, salaries or expenses to any person or other entity; and (f) has never been involved in any bankruptcy, receivership or other such action.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">4.6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Materials to be Supplied.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">All materials supplied and to be supplied to the Investor by the Company are true, accurate and complete documents, including, but not limited to, the Certificate of Incorporation and By-laws of the Company, as amended to date, and any and all other documents.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">4.7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Information.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company acknowledges that true, accurate and complete copies of the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2023, and Quarterly Reports on Form 10-Q for the quarter ended June 30, September 30, and December 31, 2023 (the "SEC Documents") are on file at www.sec.gov. None of the SEC Documents nor any other form, statement, notice, report, or document filed by the Company with the SEC prior to the date hereof contained, as of their respective dates, any untrue statement of a material fact or omitted to state a material fact necessary in order to make the statements contained therein not misleading.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company acknowledges that nothing has occurred with respect to which the Company would be required to file any report on Form 8-K. Between and until the Closing, the Company will provide to the Investor copies of any and all reports filed by the Company with the SEC and any and all reports or notices delivered to the stockholders of the Company concurrently with the filing or delivery thereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The shares of the Common Stock are listed and traded on the NYSE-American.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">4.8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">The balance sheets, and statements of operations, cash flows and shareholders' equity contained in the SEC Documents have been prepared in accordance with generally accepted accounting principles applied on a basis consistent with prior periods (and, in the case of unaudited financial information, on a basis consistent with year-end audits). The financial statements included in the Company's Annual Report on Form 10-K filed with the SEC are as audited by, and include the related opinions of Manohar Chowdhry and Associates, the Company's current independent registered public accounting firm. The financial information included in the Company's Quarterly Reports on Form 10- Q filed with the SEC are unaudited but reflect all adjustments (including normally recurring accounts), which the Company considers necessary for a fair presentation of such information.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">4.9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Disclosure.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">There is no fact relating to the Company that the Company has not disclosed to the Investor in writing which materially and adversely affects nor, insofar as the Company can now foresee, will materially and adversely affect, the condition</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="3" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">3</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">(financial or otherwise) of the Company. No representation or warranty by the Company herein and no information disclosed in the disclosure schedules and exhibits hereto by the Company contains any untrue statement of a material fact or omits to state a material fact necessary to make the statements contained herein or therein not misleading.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Covenants.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">5.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NYSE AMERICAN.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">Pursuant to exemptions, set out in the NYSE American company handbook, in no event shall the Company be obligated to issue a number of Shares under this Agreement equal to more than 19.9% of its outstanding shares of Common Stock, determined immediately prior to the Closing, and the Company agrees not to issue shares of Common Stock in any other related transaction or series of transactions (whether an additional financing or an acquisition transaction in consideration, in whole or part, for Common Stock) that would be integrated herewith and counted together so as to exceed such threshold.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Piggy-Back Registration Rights.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">6.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Participation in Registrations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">Subject to Section 6.2 and the other provisions of this Section 6, if the Company shall determine to register any Common Stock pursuant to the Securities Act, the Company will use its best efforts to include in such registration such number of Shares as it reasonably believes (or, if such offering shall be an underwritten public offering of securities, as the underwriter (the "Underwriter") advises the Company in writing) can be sold in such offering without adversely affecting its (or the Underwriter's) ability to effect an orderly distribution of such securities (the "Registrable Shares").</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">6.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Underwritten Offerings.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">In the event a registration giving rise to the Investor's rights pursuant to Section 6.1 relates to an underwritten offering of securities, the Investor's right to registration pursuant to Section shall be conditioned upon its (a) participation in such underwriting, (b) inclusion of the Registrable Shares therein and (c) execution of all Underwriting Documents requested by the Underwriter with respect thereto. In the event the Underwriter determines that the aggregate number of shares proposed for inclusion in such offering (the "Aggregate Amount") exceeds the number of shares that it would be advisable to include in such offering (the "Recommended Amount"), the number of Registrable Shares may be reduced on a pro rata basis by the Company to the extent necessary to bring the Aggregate Amount down to the Recommended Amount.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">6.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Expenses.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">The Company shall bear all of the expenses incurred in connection with an offering of the type described in this Section 6, including, without limitation, SEC filing fees and the fees (up to a maximum aggregate amount of $2,500) of separate counsel retained with respect thereto by the Investor.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">6.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indemnification.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">The Company and the Investor will indemnify the other party hereto against all claims, losses, damages and liabilities (or actions in respect thereof) arising out of or based on any untrue statement (or alleged untrue statement) of a material fact contained in any prospectus or other document (including any related registration statement, notification or the like) incident to any registration of the type described in Section 6.1, or any omission (or alleged omission) to state in any such document a material fact required to be stated therein or necessary to make the statements therein not misleading, and will reimburse such indemnified party for any legal and any other expenses reasonably incurred in connection with investigating and defending any such claim, loss, damage, liability or action, provided that no party will be eligible for indemnification hereunder to the extent that any such claim, loss, damage, liability or expense arises out of or is based on any untrue statement or omission based upon written information furnished by such party for use in connection with such registration.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">6.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cooperation by Holder.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">The Investor shall furnish to the Company or the Underwriter, as applicable, such information regarding the Investor and the distribution proposed by it as the Company may reasonably request in connection with any registration or offering referred to in this Section 6. The Investor shall cooperate as reasonably requested by the Company in connection with the preparation of the registration statement with respect to such registration, and for so long as the Company is obligated to file and keep effective such registration statement, shall provide to the Company, in writing, for use in the registration statement, all such information regarding the Investor and its plan of distribution of the Shares included in such registration as may be reasonably necessary to enable the Company to prepare such registration statement, to maintain the currency and effectiveness thereof and otherwise to comply with all applicable requirements of law in connection therewith.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="4" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">4</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">6.6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Excluded Offerings.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">The Investor's rights pursuant to Section 6.1 shall not apply to any registrations on any registration form which does not permit secondary sales or does not include substantially the same information as would be required to be included in a registration statement covering the offering and sale of the Shares. Moreover, the rights described in Section 6.1 shall not be available to the Investor if, in the opinion of counsel to the Company, all of the Shares then held by the Investor could be sold without registration in a transaction complying with Rule 144 under the Securities Act.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Transfer Restrictions.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">7.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Securities Act Restrictions.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">Notwithstanding anything to the contrary in this Agreement, the Investor shall not Transfer any of the Shares unless and until the Company has received an opinion of counsel reasonably satisfactory to it that the Shares may be sold pursuant to an exemption from registration under the Securities Act, the availability of which is established to the reasonable satisfaction of the Company, or a registration statement relating to the Shares has been filed by the Company and declared effective by the SEC.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">Within 15 days from the Closing, the Company shall file with the SEC the registration statement relating to the Shares and to furnish the proof documents to the Investor.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">In the event the Shares cannot be quoted and become tradeable in nature due to whatsoever reason (but without attributable to the fault of the Investor), then the Company shall indemnify and keep the Investor indemnified in full for all costs, damages and losses suffered.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">7.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restrictions in Connection with Underwritten Offerings.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">Notwithstanding anything to the contrary in this Agreement, the Investor shall not Transfer any of the Shares for such time before or following the effective date of a registration statement with respect to a public offering of securities of the Company as shall be reasonably requested by an underwriter of such securities and agreed to by the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">7.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-Compliant Transfers.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">Any Transfer or purported Transfer of Shares made in violation of the provisions of this Section 7 shall be null and void and without effect.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Conditions to Closing of the Investor.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">The obligations of the Investor to affect the transactions contemplated by this Agreement are subject to the fulfillment at or prior to the Closing Date of the conditions listed below.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">8.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Representations and Warranties.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">The representations and warranties made by the Company in Section 4 shall be true and correct in all material respects at the time of Closing as if made on and as of such date.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">8.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Approvals.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">All authorizations, approvals or permits, if any, of any governmental authority or regulatory body that are required in connection with the lawful issuance of the Shares by the Company pursuant to this Agreement, shall have been duly obtained by the Company and shall be effective on and as of the Closing Date.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">8.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Corporate Proceedings.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">All corporate and other proceedings required to be undertaken by the Company in connection with the transactions contemplated hereby shall have occurred, and all documents and instruments incident to such proceedings shall be reasonably satisfactory in substance and form to the Investors.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Conditions to Closing of the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">The obligations of the Company to effect the transactions contemplated by this Agreement are subject to the fulfillment at or prior to the Closing Date of the conditions listed below.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">9.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Representations and Warranties.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="5" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">5</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">The representations and warranties made by the Investor in Section 3 shall be true and correct in all material respects at the time of Closing as if made on and as of such date.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">9.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Corporate Proceedings.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">All corporate and other proceedings required to be undertaken by the Investor in connection with the transactions contemplated hereby shall have occurred, and all documents and instruments incident to such proceedings shall be reasonably satisfactory in substance and form to the Company.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Miscellaneous.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">10.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restrictive Legend.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The certificate representing the Shares shall bear a legend containing a disclosure statement in substantially the following form:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">The securities represented by this certificate (the "Shares") have not been registered under the Securities Act of 1933, as amended (the "Securities Act"). The Shares may not be offered for sale, sold, transferred, or otherwise disposed of except pursuant to an effective registration statement under the Securities Act or an exemption from registration under the Securities Act, which exemption is confirmed in an opinion of counsel satisfactory to the Company. The sale, transfer or other disposition of the Shares is restricted by the provisions of the 2024 Stock Purchase Agreement, dated, in respect of the Shares, a copy of which may be obtained at no cost by written request made by the holder of record of this certificate to the Company at its principal executive offices.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The holder of Shares registered pursuant to the Securities Act and qualified under applicable state securities laws may exchange such Shares for new securities that shall bear a legend which omits the first two sentences of the legend set forth in paragraph (a) of this Section 10.1.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">10.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notices.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">All notices, requests, demands and other communications provided in connection with this Agreement shall be in writing and shall be deemed to have been duly given at the time when hand delivered, delivered by express courier, or sent by facsimile (with receipt confirmed by the sender's transmitting device) in accordance with the contact information provided below or such other contact information as the parties may have duly provided by notice.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">The Company:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">IGC Pharma, Inc.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">10224, Falls Road</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">Potomac, Maryland 20854</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">Telephone: (301) 983-0998</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">Attention: Claudia Grimaldi, Vice President cgrimaldi@igcpharma.com</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">With a copy to:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">Olshan Frome Wolosky LLP</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">1325 Avenue of the Americas</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">New York, New York 10019</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">Telephone: (212) 451-2300</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">Attention: Kenneth Schlesinger, Esq.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">KSchlesinger@olshanlaw.com</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">The Investor:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">As per the contact information provided in Exhibit B.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">10.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Survival of Representations and Warranties.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">Each party hereto covenants and agrees that the representations and warranties of such party contained in this Agreement shall survive (a) any investigation made by the Company or the Investor and (b) the Closing.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">10.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Entire Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">This Agreement contains the entire agreement between the parties hereto in respect of the subject matter contained herein and supersedes all prior agreements and understandings of the parties, oral and written, with respect to the subject matter contained herein.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">10.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Assignment.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="6" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">6</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">This Agreement, and the rights and obligations of a party hereunder, may not be assigned or Transferred by the Investor without the prior written consent of the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">10.6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Binding Effect; Benefits.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">This Agreement and all the provisions hereof shall be binding upon and inure to the benefit of the parties hereto and their respective successors and permitted assigns; nothing in this Agreement, expressed or implied, is intended to confer on any persons other than the parties hereto, or their respective successors and permitted assigns, any rights, remedies, obligations or liabilities under or by reason of this Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">10.7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amendment; Waivers.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">All modifications or amendments to this Agreement shall require the written consent of the Company and the Investor. No waiver of any breach, noncompliance or nonfulfillment of any of the provisions of this Agreement shall be effective unless set forth in a written instrument executed by the party against whom such waiver is sought; and no waiver of any such breach, noncompliance or nonfulfillment shall be construed to be a waiver of any other or subsequent breach, noncompliance or nonfulfillment.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">10.8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Applicable Law; Disputes.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">This Agreement shall be governed by and construed in accordance with the laws of the State of New York without giving effect to the conflict of law provisions thereof, and the parties hereto irrevocably submit to the exclusive jurisdiction of the United States District Court for the Southern District of New York, or, if jurisdiction in such court is lacking, the Supreme Court of the State of New York, New York County, in respect of any dispute or matter arising out of or connected with this Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">10.9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Further Assurances.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">Each party hereto shall do and perform or cause to be done and performed all such further acts, and shall execute and deliver all such other agreements, certificates, instruments and documents, as any other party hereto reasonably may request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">10.10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Counterparts.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which taken together shall constitute one and the same instrument.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Actions Required at Future Shareholders Meetings.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">As additional and material consideration for this Agreement, the Investor hereby agree and warrant that they shall vote in favor of and in accordance with the recommendations of the Company's Board of Directors at each of (i) the seven (7) consecutive annual shareholders&#8217; meetings immediately following execution of this Agreement and (ii) all special shareholders&#8217; meetings that are held prior to the eighth annual shareholders meeting immediately following execution of this Agreement. The Investor agrees that in the event the Investor is unable to vote the shares, timely, it hereby authorizes the Company to cast the vote on its behalf. In furtherance of this Section 11 the Investor shall sign the irrevocable proxy attached hereto as Exhibit D. The parties acknowledge that this is a material provision of this Agreement, and the failure to comply with this provision shall be grounds for the Company to seek rescission of the Agreement in the event of any breach.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">SIGNATURE PAGE FOLLOWS</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">******************************</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="7" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">7</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">IN WITNESS WHEREOF, each of the Company and the Investor has caused this Agreement to be executed as of the date below.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">For IGC Pharma, Inc.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For Investor(s) as set out in Exhibit B.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;"><u>/s/ Claudia Grimaldi </u><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<u>/s/ Loo See Yuen&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</u></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">Claudia Grimaldi&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Name: Loo See Yuen</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">Vice President &amp; CCO&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Authorized signatory</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">Date: March 22, 2024&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Date: March 22, 2024&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:72pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="8" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">8</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>EXHIBIT A</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: top; width: 49.8%; border-top: 1px solid black; border-left: 1px solid black; border-image: initial;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 6pt;">Consideration</p>
			</td>
			<td style="vertical-align: top; width: 50.1%; border-top: 1px solid black; border-right: 1px solid black; border-left: 1px solid black; border-image: initial;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 6pt;">$3,000,000</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 49.8%; border-top: 1px solid black; border-left: 1px solid black; border-image: initial;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 6pt;">Purchase price</p>
			</td>
			<td style="vertical-align: top; width: 50.1%; border-top: 1px solid black; border-right: 1px solid black; border-left: 1px solid black; border-image: initial;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 6pt;">$0.34</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid black; vertical-align: top; width: 49.8%; border-top: 1px solid black; border-left: 1px solid black; border-image: initial;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 6pt;">Total of the Shares to be delivered</p>
			</td>
			<td style="border: 1px solid black; vertical-align: top; width: 50.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&nbsp;8,823,529</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Wire transfer information for &#8220;The Consideration&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: top; width: 50%; border-top: 1px solid black; border-left: 1px solid black; border-image: initial;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 6pt;">Name of Bank</p>
			</td>
			<td style="vertical-align: top; width: 50%; border-top: 1px solid black; border-right: 1px solid black; border-left: 1px solid black; border-image: initial;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 50%; border-top: 1px solid black; border-left: 1px solid black; border-image: initial;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 6pt;">Address</p>
			</td>
			<td style="vertical-align: top; width: 50%; border-top: 1px solid black; border-right: 1px solid black; border-left: 1px solid black; border-image: initial;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 50%; border-top: 1px solid black; border-left: 1px solid black; border-image: initial;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 6pt;">Name of Bank Manager</p>
			</td>
			<td style="vertical-align: top; width: 50%; border-top: 1px solid black; border-right: 1px solid black; border-left: 1px solid black; border-image: initial;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 50%; border-top: 1px solid black; border-left: 1px solid black; border-image: initial;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 6pt;">Phone number of Bank</p>
			</td>
			<td style="vertical-align: top; width: 50%; border-top: 1px solid black; border-right: 1px solid black; border-left: 1px solid black; border-image: initial;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 50%; border-top: 1px solid black; border-left: 1px solid black; border-image: initial;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 6pt;">Name of Account Address of Company</p>
			</td>
			<td style="vertical-align: top; width: 50%; border-top: 1px solid black; border-right: 1px solid black; border-left: 1px solid black; border-image: initial;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">IGC Pharma, Inc.</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10224 Falls Road, Potomac, MD 20854</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 50%; border-top: 1px solid black; border-left: 1px solid black; border-image: initial;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 6pt;">Account number</p>
			</td>
			<td style="vertical-align: top; width: 50%; border-top: 1px solid black; border-right: 1px solid black; border-left: 1px solid black; border-image: initial;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 50%; border-top: 1px solid black; border-left: 1px solid black; border-image: initial;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 6pt;">Swift Code</p>
			</td>
			<td style="vertical-align: top; width: 50%; border-top: 1px solid black; border-right: 1px solid black; border-left: 1px solid black; border-image: initial;">&nbsp;</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid black; vertical-align: top; width: 50%; border-top: 1px solid black; border-left: 1px solid black; border-image: initial;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 6pt;">Purpose of wire</p>
			</td>
			<td style="border: 1px solid black; vertical-align: top; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Share subscription</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="1" data-prefix="A-" data-suffix="" style="text-align: center; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">A-1</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>EXHIBIT B</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: top; width: 50%; border-top: 1px solid black; border-left: 1px solid black; border-image: initial;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 6pt;">Name of Investor:</p>
			</td>
			<td style="vertical-align: top; width: 50%; border-top: 1px solid black; border-right: 1px solid black; border-left: 1px solid black; border-image: initial;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Bradbury Strategic Investment Fund A</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 50%; border-top: 1px solid black; border-left: 1px solid black; border-image: initial;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 6pt;">Address Investor:</p>
			</td>
			<td style="vertical-align: top; width: 50%; border-top: 1px solid black; border-right: 1px solid black; border-left: 1px solid black; border-image: initial;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 50%; border-top: 1px solid black; border-left: 1px solid black; border-image: initial;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 6pt;">Director:</p>
			</td>
			<td style="vertical-align: top; width: 50%; border-top: 1px solid black; border-right: 1px solid black; border-left: 1px solid black; border-image: initial;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Loo See Yuen</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 50%; border-top: 1px solid black; border-left: 1px solid black; border-image: initial;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 6pt;">Passport Number:</p>
			</td>
			<td style="vertical-align: top; width: 50%; border-top: 1px solid black; border-right: 1px solid black; border-left: 1px solid black; border-image: initial;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">KXXXXXXA</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 50%; border-top: 1px solid black; border-bottom: 1px solid black; border-left: 1px solid black; border-image: initial;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 6pt;">Non-U.S. Person certificate</p>
			</td>
			<td style="vertical-align: top; width: 50%; border: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Exhibit C attached</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="1" data-prefix="B-" data-suffix="" style="text-align: center; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">B-1</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Exhibit C:</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Non-U.S. Person Certificate</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">To: IGC Pharma, Inc.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:4.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>1.</b></p>
			</td>
			<td style="vertical-align:top;width:92%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>The undersigned hereby represents, warrants and certifies that:</b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:4.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(a)</p>
			</td>
			<td style="vertical-align:top;width:92.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">It is not a &#8220;U.S. Person&#8221;&nbsp;(as such term is defined by Rule 902 of Regulation S under the U.S. Securities Act) and is not acquiring the Shares, directly or indirectly, for the account or benefit of any U.S. person.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 78pt;text-indent:-36pt;">Rule 902 under the U.S. Securities Act, defines a &#8220;U.S. Person&#8221; as: (A)Any Natural person resident in the United States;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:14.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(B)</p>
			</td>
			<td style="vertical-align:top;width:82.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Any partnership or corporation organized or incorporated under the laws of the United States;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 78pt;text-indent:1pt;">(C)&nbsp;&nbsp;&nbsp;&nbsp;Any estate of which any execution or administrator is a U.S. Person; (D)Any trust of which any trustee is a U.S. Person;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:14.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(E)</p>
			</td>
			<td style="vertical-align:top;width:82.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Any agency or branch of a foreign entity located in the United States;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:14.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(F)</p>
			</td>
			<td style="vertical-align:top;width:82.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Any non-discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary for the benefit or account of a U.S. Person;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:14.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(G)</p>
			</td>
			<td style="vertical-align:top;width:82.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Any discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary organized, incorporated, or (if an individual) resident in the United States; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:14.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(H)</p>
			</td>
			<td style="vertical-align:top;width:82.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Any partnership or corporation if:</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:27.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(1)</p>
			</td>
			<td style="vertical-align:top;width:69.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Organized or incorporated under the laws of any foreign jurisdiction; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:27.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(2)</p>
			</td>
			<td style="vertical-align:top;width:69.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Formed by a U.S. Person principally for the purpose of investing in securities not registered under the Securities Act, unless it is organized or incorporated, and owned, by accredited investors (as defined in Rule 501(a) under the Securities Act) who are not natural person, estates or trusts.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The following are not &#8220;U.S. Persons:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:14.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(A)</p>
			</td>
			<td style="vertical-align:top;width:82.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Any discretionary account or similar account (other than an estate or trust) held for the benefit or account of a Non-U.S. Person by a dealer or other professional fiduciary organized, incorporated, or (if any individual) resident in the United States;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:14.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(B)</p>
			</td>
			<td style="vertical-align:top;width:82.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Any estate of which any professional fiduciary acting as executor or administrator is a U.S. Person if:</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:21.1%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(1)</p>
			</td>
			<td style="vertical-align:top;width:75.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">An executor or administrator of the estate who is not a U.S. Person has sole or shared investment discretion with respect to the assets of the estate; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:21.1%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(2)</p>
			</td>
			<td style="vertical-align:top;width:75.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The estate is governed by foreign law;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:14.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(C)</p>
			</td>
			<td style="vertical-align:top;width:82.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Any trust of which any professional fiduciary acting as trustee is a U.S. Person, if a trustee who is not a U.S. Person has sole or shared investment discretion with respect to the trust assets, and no beneficiary of the trust (and no settler if the trust is revocable) is a U.S. Person;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:14.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(D)</p>
			</td>
			<td style="vertical-align:top;width:82.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Any employee benefit established and administered in accordance with the law of a country other than the United States and customary practices and documentation of such country;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:14.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(E)</p>
			</td>
			<td style="vertical-align:top;width:82.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Any agency or branch of a U.S. person located outside the United States if:</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="1" data-prefix="C-" data-suffix="" style="text-align: center; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">C-1</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:20.9%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(1)</p>
			</td>
			<td style="vertical-align:top;width:75.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The agency or branch operates for valid business reasons; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:20.9%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(2)</p>
			</td>
			<td style="vertical-align:top;width:75.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The agency or branch is engaged in the business of insurance or banking and is subject to substantive insurance or banking regulation, respectively, in the jurisdiction where located; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:14.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(F)</p>
			</td>
			<td style="vertical-align:top;width:82.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The International Monetary Fund, the International Bank for Reconstruction and Development, the Inter-American Development Bank, the Asian Development Bank, the African Development Bank, the United Nations, and their agencies, affiliates and pension plans, and any other similar international organizations, their agencies, affiliates and pension plans.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:4.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(b)</p>
			</td>
			<td style="vertical-align:top;width:92.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The offer and scale of the Shares was made in an &#8220;offshore transaction&#8221;&nbsp;(as defined under Regulation Sunder the U.S. Securities Act), in that:</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:10.9%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(i)</p>
			</td>
			<td style="vertical-align:top;width:85.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The undersigned was outside the United States at the time the buy order for such Shares was originated; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:10.9%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(ii)</p>
			</td>
			<td style="vertical-align:top;width:85.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The offer to sell the Shares was not made to the undersigned in the United States.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:4.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(c)</p>
			</td>
			<td style="vertical-align:top;width:92.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The transaction: (i) has not been pre-arranged with a purchaser located inside of the United States or is a U.S. Person; and (ii) is not part of a plan or scheme to evade the registration requirements of the U.S. Securities Act.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:4.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>2.</b></p>
			</td>
			<td style="vertical-align:top;width:92.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>The undersigned hereby covenants that:</b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:4.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(a)</p>
			</td>
			<td style="vertical-align:top;width:92.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">During the period prior to one year after the Closing (the &#8220;<b>Restricted Period</b>&#8221;<b>) </b>it will not engage in hedging transactions with regard to the Shares unless such transactions are made in compliance with the U.S. Securities Act;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:4.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(b)</p>
			</td>
			<td style="vertical-align:top;width:91.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">If it decides to offer, sell or otherwise transfer any of the Shares, it will not offer, sell or otherwise transfer any of such Shares directly or indirectly, unless:</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:11.5%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(i)</p>
			</td>
			<td style="vertical-align:top;width:85.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The sale is to the Company;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:11.5%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(ii)</p>
			</td>
			<td style="vertical-align:top;width:85.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The sale is made outside the United States in a transaction meeting the requirements of Regulation Sunder the U.S. Securities Act and in compliance with applicable local laws and regulations; provided, however, that during the period prior to the expiration of the Restrictive Period no sale may be made to any U.S. Person or for the account or benefit of the U.S. person (other than a distributor) and all purchasers of such Shares will be required to execute and deliver to the Company a certificate substantially in the form hereof;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:11.5%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(iii)</p>
			</td>
			<td style="vertical-align:top;width:85.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The sale is made in the United States pursuant to the exemption from the registration requirements under the U.S. Securities Act provided by Rule 144 thereunder and in accordance with any applicable state securities or &#8220;blue sky&#8221;&nbsp;laws and the purchaser has prior to such sale furnished to the Company an opinion of counsel reasonably satisfactory to the Company to the effect that such transaction does not require registration pursuant to Rule 144 under the U.S. Securities Act;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:11.1%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(iv)</p>
			</td>
			<td style="vertical-align:top;width:85.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Shares are sold in the United States in a transaction that does not require registration under U.S. Securities Act or any applicable state laws and regulations governing the offer and sale of securities, and it has prior to such sale furnished to the Company an opinion of counsel reasonably satisfactory to the Company to the effect that such transaction does not require registration; or</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:11.1%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(v)</p>
			</td>
			<td style="vertical-align:top;width:85.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The sale is made in the United States pursuant to an effective registration statement filed under the U.S. Securities Act.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="2" data-prefix="C-" data-suffix="" style="text-align: center; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">C-2</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:2%;">&nbsp;</td>
			<td style="vertical-align:top;width:2.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>3.</b></p>
			</td>
			<td style="vertical-align:top;width:95.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>The undersigned acknowledges and agrees that:</b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:4.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(a)</p>
			</td>
			<td style="vertical-align:top;width:92%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Shares are and will be &#8220;restricted securities&#8221;&nbsp;as that term is defined in Rule 144 under the&nbsp;U.S. Securities Act, and the certificates representing the Shares, as well as all certificates issued in exchange for or in substitution of the foregoing, until such time as is no longer required under the applicable requirements of the U.S. Securities Act or applicable state securities laws, will be subject to the terms of and bear, on the face of such certificate, a legend in substantially the following for:</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 43pt;text-indent:1pt;">THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933 (THE &#8220;U.S. SECURITIES ACT&#8221;) OR ANY STATE SECURITIES LAWS AND ARE BEING OFFERED AND SOLD IN RELIANCE ON EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF THE U.S. SECURITIES ACT. THESE SECURITIES ARE RESTRICTED SECURITIES (AS DEFINED UNDER RULE 144 UNDER THE U.S. SECURITIES ACT) AND MAY NOT BE SOLD, TRANSFERRED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF FOR VALUE EXCEPT IN ACCORDANCE WITH THE PROVISIONS OF REGULATIONS PROMULGATED UNDER THE U.S. SECURITIES ACT, PURSUANT TO REGISTRATION UNDER THE U.S. SECURITIES ACT, OR PURSUANT TO AN AVAILABLE EXEMPTION FROM REGISTRATION THEREUNDER.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 43pt;text-indent:1pt;">DURING THE PERIOD PRIOR TO <b>ONE YEAR AFTER THE CLOSING </b>(THE &#8220;<b>RESTRICTED PERIOD</b>&#8221;<b>), </b>THE SECURITIES REPRESENTED BY THIS CERTIFICATE MAY NOT BE OFFERED OR SOLD, DIRECTLY OR INDIRECTLY WITHIN THE UNITED STATES, TO A U.S. PERSON (AS DEFINIED IN REGULATIONS UNDER THE U.S. SECURITIES ACT), OR FOR THE ACCOUNT OR BENEFIT OF A U.S. PERSON, EXCEPT PURSUANT TO REGISTRATION UNDER THE U.S. SECURITIES ACT, OR PURSUANT TO AN AVAILABLE EXEMPTION FROM REGISTRATION THEREUNDER. DURING THE RESTRICTED PERIOD HEDGING TRANSACTIONS INVOLYING THESE SECURITIES MAY NOT BE CONDUCTED UNLESS SUCH TRANSACTIONS ARE MADE IN COMPLIANCE WITH THE U.S. SECURITES ACT. THIS PARAGRAPH SHALL HAVE NO FURTHER EFFECT SUBSEQUENT TO THE EXPIRATION OF THE RESTRICTED PERIOD AND THEREAFTER MAY BE REMOVED.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:4.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(b)</p>
			</td>
			<td style="vertical-align:top;width:91.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company will refuse to register any sale of Shares made in breach of the provisions hereof.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:4.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(c)</p>
			</td>
			<td style="vertical-align:top;width:91.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The addressees of this certificate and others will rely upon the truth and accuracy of the foregoing acknowledgements, representations, warranties and agreements, and irrevocably authorizes the addressees of this certificate to produce the same or a copy thereof to any interested party in any administrative or legal proceeding or official enquiry with respect to the matters set forth herein. The undersigned further agrees that if any of acknowledgements, representations, warranties or agreements made herein is no longer accurate, it shall promptly notify the Company.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:54%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: top; width: 100.1%; border-top: 1px solid black; border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 6pt;">Signed for Investor: /s/ Loo See Yuen&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 100.1%; border-top: 1px solid black; border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 6pt;">Name: Loo See Yuen</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 100.1%; border-top: 1px solid black; border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&nbsp;Signature of witness: /s/ Ernest Cheong&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 100.1%; border-top: 1px solid black; border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 6pt;">Name of Witness: Ernest Cheong</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 100.1%; border-width: 1px; border-style: solid; border-color: black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 6pt;">Date: March 22, 2024</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="3" data-prefix="C-" data-suffix="" style="text-align: center; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">C-3</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Exhibit D</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>IRREVOCABLE PROXY</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The undersigned stockholder of IGC Pharma, Inc., a Maryland corporation (the &#8220;Company&#8221;) hereby irrevocably (to the fullest extent permitted by law) appoints and constitutes Claudia Grimaldi the attorney and proxy of the undersigned with full power of substitution and resubstitution, to the full extent of the undersigned&#8217;s rights with respect to the number of shares of common stock of the Company as set forth below (the &#8220;Shares&#8221;) owned by the undersigned as of March 22, 2024.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">This proxy is irrevocable, is coupled with an interest and is granted in connection with the purchase of the Shares pursuant to that certain 2024 Stock Purchase Agreement, dated March 22, 2024, between the undersigned and the Company (the &#8220;2024 Stock Purchase Agreement&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">If the undersigned has not exercised the undersigned&#8217;s voting rights on or before two business day prior to any meeting of stockholders of the Company, the attorney and proxy named above will be empowered, and may exercise this proxy, to vote the Shares at such meeting of stockholders of the Company, however called, and at any adjournment thereof, or in any written action by consent of stockholders of the Company in accordance with Section 11 of the 2024 Stock Purchase Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Any obligation of the undersigned hereunder shall be binding upon the heirs, successors and assigns of the undersigned.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">This proxy has been granted with respect to 8,823,529 Shares of IGC&#8217;s Common Stock.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:49.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:50.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Signed for Investor:</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:49.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:50.8%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:49.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:50.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By:<u>&nbsp;/s/ Loo See Yuen&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</u></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:49.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:50.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Name: Loo See Yuen</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:49.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:50.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Authorized Signatory</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Date: March 22, 2024</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:49.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:50.8%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="1" data-prefix="D-" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">D-1</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>ex_645637.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html><head>
	<title>ex_645637.htm</title>
	<!-- Generated by ThunderDome Portal - 3/26/2024 11:08:02 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Exhibit 99.1</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img src="ex_645637img001.jpg" style="width:136;height:84;" alt="ex_645637img001.jpg"></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><u>PRESS RELEASE ISSUED ON MARCH 26, 2024</u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">POTOMAC, March 26, 2024 - IGC Pharma, Inc. (NYSE American: IGC) (&#8220;IGC&#8221; or the &#8220;Company&#8221;) today announced a $3 million strategic investment from funds managed by Bradbury Asset Management (Hong Kong) Limited (&#8220;Bradbury&#8221;), a leading asset management firm.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On March 22, 2024, the Company entered into a Share Purchase Agreement (the &#8220;SPA&#8221;) with Bradbury, subject to the terms and subject to the conditions set forth in the SPA. The investment is for approximately $3 million in gross proceeds at the March 21, 2024, closing price of $0.34. The funds will support general corporate purposes and the Company&#8217;s advancement of its investigational medicines including IGC-AD1.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The completion of the private placement is subject to customary closing conditions, including approval by the NYSE. Under the terms of the SPA, IGC will issue 8,823,529 shares of common stock. The shares are unregistered and are not immediately tradable.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Please note that this press release does not constitute an offer to sell or a solicitation of an offer to buy these securities. Furthermore, there shall be no sale of the securities in any state in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of the respective state.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>About IGC Pharma Inc. (IGC):</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">IGC Pharma Inc. (&#8220;IGC&#8221;) is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness. The Company's mission is to transform the landscape of Alzheimer's treatment with a robust pipeline of five promising drug candidates. IGC-AD1 and LMP target the hallmarks of Alzheimer's disease, including neuroinflammation, A&#946; plaques, and neurofibrillary tangles. IGC-AD1 is currently undergoing a Phase 2 clinical trial for agitation in dementia associated with Alzheimer's (clinicaltrials.gov, CT05543681). TGR-63 disrupts the progression of Alzheimer's by targeting A&#946; plaques. IGC-M3, currently in preclinical development, aims to inhibit the aggregation of A&#946; plaques, potentially impacting early-stage Alzheimer's. IGC-1C, also in preclinical stages, targets tau protein and neurofibrillary tangles, representing a forward-thinking approach to Alzheimer's therapy. In addition to its drug development pipeline, IGC Pharma seeks to leverage Artificial Intelligence (&#8220;AI&#8221;) for Alzheimer's research. Their AI projects encompass various areas, including clinical trial optimization and early detection of Alzheimer's.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Forward-Looking Statements:</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">This press release contains forward-looking statements. These forward-looking statements are based largely on IGC Pharma&#8217;s expectations and are subject to several risks and uncertainties, certain of which are beyond IGC Pharma&#8217;s control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company&#8217;s failure or inability to commercialize one or more of the Company&#8217;s products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required, or government regulations affecting AI or the AI algorithms not working as intended or producing accurate predictions; general economic conditions that are less favorable than expected; the FDA&#8217;s general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC Pharma&#8217;s U.S. Securities and Exchange Commission ("SEC") filings. IGC Pharma incorporates by reference the human trial disclosures and Risk Factors identified in its Annual Report on Form 10-K filed with the SEC on July 7, 2023, and Quarterly Report on Form 10-Q filed with the SEC on February 14, 2024, as if fully incorporated and restated herein. Considering these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Contact:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Investors<br>
IMS Investor Relations<br>
Rosalyn Christian/Walter Frank<br>
igc@imsinvestorrelations.com<br>
(203) 972-9200</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Media<br>
JVPRNY<br>
Janet Vasquez<br>
<u>jvasquez@jvprny.com</u><br>
(212) 645-5498</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>igc-20240322.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Wed Mar 27 22:37:24 UTC 2024 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2024" targetNamespace="http://www.igcinc.us/20240322" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:igc="http://www.igcinc.us/20240322" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="igc-20240322_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="igc-20240322_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="igc-20240322_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt9uvRsJTXMeMewLyH9HKj6I6pbvcDxjLAKD9Z7zGpK2qQstFsfCu8xSrtW9H2+v0Xv0rh9+KH/Pz8D0bXTVzCQTQCC6nPug5x3Q1UInPHgbEGZWRPbDSOOR8Wxhx84uVee2wOCsvIBVXQhjcay/jyj+BzF6F5eWXZxkWrE+b343GSqCsHkN4aGrn0sPeSOmktnQGTXPn6z0H4b8vZ43AW2MYp8n1m14bD3XDD/plQ+aZA==] CSR-->
      <link:roleType roleURI="http://www.igcinc.us/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2024" schemaLocation="https://xbrl.sec.gov/sic/2024/sic-2024.xsd"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>igc-20240322_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Wed Mar 27 22:37:24 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="igc-20240322.xsd#DocumentAndEntityInformation" roleURI="http://www.igcinc.us/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.igcinc.us/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="8" xbrldt:closed="true"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt9uvRsJTXMeMewLyH9HKj6I6pbvcDxjLAKD9Z7zGpK2qQstFsfCu8xSrtW9H2+v0Xv0rh9+KH/Pz8D0bXTVzCQTQCC6nPug5x3Q1UInPHgbEGZWRPbDSOOR8Wxhx84uVee2wOCsvIBVXQhjcay/jyj+BzF6F5eWXZxkWrE+b343GSqCsHkN4aGrn0sPeSOmktnQGTXPn6z0H5uSdFJYCiUf0kmD0gU+b85luRwZTw62bg==] CSR-->
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="22" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>igc-20240322_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Wed Mar 27 22:37:24 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt9uvRsJTXMeMewLyH9HKj6I6pbvcDxjLAKD9Z7zGpK2qQstFsfCu8xSrtW9H2+v0Xv0rh9+KH/Pz8D0bXTVzCQTQCC6nPug5x3Q1UInPHgbEGZWRPbDSOOR8Wxhx84uVee2wOCsvIBVXQhjcay/jyj+BzF6F5eWXZxkWrE+b343GSqCsHkN4aGrn0sPeSOmktnQGTXPn6z0H4b8vZ43AW2MeabV/Ad26cLxRTuTVxoL0g==] CSR-->
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl0" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl0" xml:lang="en-US">Entity Tax Identification Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl0" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl0" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl0" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl0" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl0" xml:lang="en-US">Soliciting Material</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl0" xml:lang="en-US">Written Communications</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl0" xml:lang="en-US">Pre-commencement Tender Offer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl0" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl0" xml:lang="en-US">Entity Address, State or Province</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl0" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl0" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl0" xml:lang="en-US">Pre-commencement Issuer Tender Offer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl0" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl0" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>igc-20240322_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Wed Mar 27 22:37:24 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="igc-20240322.xsd#DocumentAndEntityInformation" roleURI="http://www.igcinc.us/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.igcinc.us/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="igc-20240322.xsd#igc_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt9uvRsJTXMeMewLyH9HKj6I6pbvcDxjLAKD9Z7zGpK2qQstFsfCu8xSrtW9H2+v0Xv0rh9+KH/Pz8D0bXTVzCQTQCC6nPug5x3Q1UInPHgbEGZWRPbDSOOR8Wxhx84uVee2wOCsvIBVXQhjcay/jyj+BzF6F5eWXZxkWrE+b343GSqCsHkN4aGrn0sPeSOmktnQGTXPn6z0H0lD54cFnWNNvij7AWhLav+/oumS3gT1YQ==] CSR-->
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>ex_645637img001.jpg
<TEXT>
begin 644 ex_645637img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !4 (@# 2(  A$! Q$!_\0
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MO[R.[:W9EAD12/W><J#GN,XHKCDK2T91TE%%% !1110 4444 %%%% !1110
24444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>igcpharma20240326_8kimg001.jpg
<TEXT>
begin 644 igcpharma20240326_8kimg001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !% & # 2(  A$! Q$!_\0
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MHU8Q:*** "DQ110 8XI:** "FL@==I (]",T44 4QH^FK)YBV-N')SGRQ5T
..  #H***+@+1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139997206331920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Mar. 22, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">IGC PHARMA, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IGC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001326205<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 22,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">MD<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-32830<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-2760393<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">10024 Falls Road<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Potomac<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20859<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">983-0998<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $.0001 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M#RP/9'I;K?%NXQ/R^AQ@/7UM0K"=XI.([12O-2#QNH%'GL>[C>4!#ZP+V.Q
M_G@>F*FX3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X %F>0IA@"
MIQ%', ;  4/2='@//GL?)=-[*CG_5U/\!%!+ P04    " !-E7M8EXJ[',
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MA1H#V#<YD 27Y*IU5%WI>:;7-Y-;2>C@W(-@[^&5C!W-CQ]W]P-02P,$%
M  @ 395[6"0>FZ*M    ^ $  !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN
M<F5L<[61/0Z#, R%KQ+E #50J4,%3%U8*RX0!?,C$A+%K@JW+X4!D#IT8;*>
M+7_OR4Z?:!1W;J"V\R1&:P;*9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2
M*+I!V#-DGNZ9HIP\_D-T==UI?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+B
MRTR6HJ@R&8HJEG!:(.+)(&UI5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#
M!!0    ( $V5>UAED'F2&0$  ,\#   3    6T-O;G1E;G1?5'EP97-=+GAM
M;*V334[#,!"%KQ)E6R4N+%B@IAM@"UUP 6-/&JO^DV=:TMLS3MI*H!(5A4VL
M>-Z\SYZ7K-Z/$;#HG?78E!U1?!0"50=.8ATB>*ZT(3E)_)JV(DJUDUL0]\OE
M@U#!$WBJ*'N4Z]4SM')OJ7CI>1M-\$V9P&)9/(W"S&I*&:,U2A+7Q<'K'Y3J
M1*BY<]!@9R(N6%"*JX1<^1UPZGL[0$I&0[&1B5ZE8Y7HK4 Z6L!ZVN+*&4/;
M&@4ZJ+WCEAIC JFQ R!GZ]%T,4TFGC",S[O9_,%F"LC*30H1.;$$?\>=(\G=
M560C2&2FKW@ALO7L^T%.6X.^D<WC_0QI-^2!8ECFS_A[QA?_&\[Q$<+NOS^Q
MO-9.&G_FB^$_7G\!4$L! A0#%     @ 395[6 =!36*!    L0   !
M         ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " !-E7M8
MZ5&CNN\    K @  $0              @ &O    9&]C4')O<',O8V]R92YX
M;6Q02P$"% ,4    " !-E7M8F5R<(Q &  "<)P  $P              @ '-
M 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( $V5>UC&&W4.1 0
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M2P$"% ,4    " !-E7M8)!Z;HJT   #X 0  &@              @ &Z$0
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " !-E7M899!Y
MDAD!  #/ P  $P              @ &?$@  6T-O;G1E;G1?5'EP97-=+GAM
7;%!+!08     "0 ) #X"  #I$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="igcpharma20240326_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.igcinc.us/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>igc-20240322.xsd</File>
    <File>igc-20240322_def.xml</File>
    <File>igc-20240322_lab.xml</File>
    <File>igc-20240322_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="igcpharma20240326_8k.htm">igcpharma20240326_8k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>igcpharma20240326_8kimg001.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "igcpharma20240326_8k.htm": {
   "nsprefix": "igc",
   "nsuri": "http://www.igcinc.us/20240322",
   "dts": {
    "schema": {
     "local": [
      "igc-20240322.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/sic/2024/sic-2024.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "igc-20240322_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "igc-20240322_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "igc-20240322_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "igcpharma20240326_8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 22
   },
   "report": {
    "R1": {
     "role": "http://www.igcinc.us/role/DocumentAndEntityInformation",
     "longName": "000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igcpharma20240326_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igcpharma20240326_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "igc_DocumentAndEntityInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.igcinc.us/20240322",
     "localname": "DocumentAndEntityInformationAbstract",
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001185185-24-000324-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001185185-24-000324-xbrl.zip
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M:=37R-K?>CWOP!XP>$!'RI/Z!=%OJ(:?JDS8>B#:U4.F7&RTH1LWVH3F@L_
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MGZ*I!V:(,NR3HI9,F!I Q/%=3$9%K=?12YURO:Y]N@'@XOH?70=51!"%'+G
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MV#%MY1'1W[[G3\<^F)AO29O@*5R\0LK(@)?">^?"!IG(BH1S@E16M#%ENO,
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MA.;KT;FH=-L/K])M^U:2#HSFN+_OE&X+]S6C>=57+JJ/G;NF<MYJ-.Z..L[
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MH-0E&J(#3&SI+V;_+26E$6.3O"S/9K-C@]>A!B2 8H<8@(H"*9GD@ &D2H
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M.G-;QU8H4]:1/F84'VK'L]ZOA'HX']XZTW9YO4AF5@](OOS\#JSW?&F $M:
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M/VM <3B'KO<\,"!\,N=0!\1+;*LYPBB*$\L&6$S&QJ8(@2&A<S>'^M$CD#&
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M#ER?7@"DKPG!?-B  ]Z:#.1N'+EP/![#CTURPD<<3^0(_&C4?"Z/V50>IR&
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MYGOPAMR/<JN^P[Q6V<'$YQ.FP5& /AZ6]5'Z5FM*,EA=G2DA;C S<_*WM,6
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M7S8T-38S-RYH=&U02P$"% ,4    " !-E7M8S2VU#TX$  #2#   $
M        @ &(2   :6=C+3(P,C0P,S(R+GAS9%!+ 0(4 Q0    ( $V5>UA9
MT4:W! 8  !PJ   4              "  01-  !I9V,M,C R-# S,C)?9&5F
M+GAM;%!+ 0(4 Q0    ( $V5>U@,*'4*W0<  $]/   4              "
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B.&MI;6<P,#$N:G!G4$L%!@     (  @ # (  )Y]      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>igcpharma20240326_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="igc-20240322.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
        </entity>
        <period>
            <startDate>2024-03-22</startDate>
            <endDate>2024-03-22</endDate>
        </period>
    </context>
    <dei:DocumentType contextRef="c0" id="ixv-379">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c0" id="ixv-47">2024-03-22</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c0" id="ixv-61">IGC PHARMA, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0" id="ixv-73">MD</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c0" id="ixv-78">001-32830</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c0" id="ixv-83">20-2760393</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c0" id="ixv-380">10024 Falls Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c0" id="ixv-381">Potomac</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c0" id="ixv-382">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c0" id="ixv-383">20859</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c0" id="ixv-384">301</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c0" id="ixv-385">983-0998</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c0" id="ixv-386">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c0" id="ixv-387">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c0" id="ixv-388">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c0" id="ixv-389">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c0" id="ixv-390">Common Stock, $.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c0" id="ixv-391">IGC</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c0" id="ixv-392">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c0" id="ixv-393">false</dei:EntityEmergingGrowthCompany>
    <dei:AmendmentFlag contextRef="c0" id="ixv-396">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="c0" id="ixv-397">0001326205</dei:EntityCentralIndexKey>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
